Alain C. Mita

DEVELOPMENT OF A FIVE-GENE HEDGEHOG SIGNATURE AS A PATIENT PRESELECTION TOOL FOR HEDGEHOG PATHWAY-TARGETED THERAPY IN MEDULLOBLASTOMA

Keith L. Ligon, Douglas Robinson, Jordi Rodon, 2013 .

Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788

Patrick Schöffski, Alain C. Mita, Josep Tabernero, 2012, Clinical Cancer Research.

Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics

Alain C. Mita, Francis J. Giles, F. Giles, 2008, Clinical Cancer Research.